The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 21, 1990

Filed:

Oct. 04, 1988
Applicant:
Inventors:

Roland K Robins, Irvine, CA (US);

Brahma S Sharma, Irvine, CA (US);

Ganapathi R Revankar, Irvine, CA (US);

Assignee:

Nucleic Acid Research Institute, Costa Mesa, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K / ; A61K / ; C07H / ;
U.S. Cl.
CPC ...
514 45 ; 514885 ; 536 23 ; 536 24 ; 424 851 ; 424 852 ;
Abstract

##STR1## 6-Amino-1-(2-deoxy-.alpha.D-erythro-pentofuranosyl)imidazo [4,5-C]pyridin-4-one (also know as .alpha.-2'-deoxy-3-deazaguanosine) is non mitogenic to human peripheral blood lymphocytes; however, it displays a potent immunoenhancing activity on human T cells. This compound causes a marked increase in both phytohemagglutinin and Concanavalin A induced proliferation of T cells. When added during allogeneic mixed lymphocyte response, it also potentiates the proliferation of alloreative T cells. The compound shows no potentiating effect on B lymphocytes activated either with Staphylococcus aureus cowan or Pokeweed mitogen, suggesting that it is mainly a T cell function immunopotentiator. The compound overcomes induced immunosuppression and is able to restore depressed proliferative responses of T cells. Further it potentiates the generation of antigen-specific primary cytotoxic T lymphocytes.


Find Patent Forward Citations

Loading…